| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Rosarin's mechanism of action involves the suppression of pro-inflammatory factors. It inhibits the expression of iNOS, IL-1β, and TNF-α. This anti-inflammatory action is observed in the kidney and prefrontal cortex of the brain in mice. Its neuroprotective effects are likely mediated through this reduction of neuroinflammation.
|
|---|---|
| ln Vitro |
The production of iNOS and cytokines in mouse BV2 cells was reduced in a concentration-dependent manner by rosarine (0-50 μg/ml; 18 hours) pretreatment for 30 minutes [1].
In vitro, rosarin has anti-inflammatory and neuroprotective effects. It suppresses the expression of the proinflammatory factors iNOS, IL-1β, and TNF-α. Its activity is studied in cell-based models of neuroinflammation. It is a cinnamyl alcohol glycoside. Its purity is 99.95%. |
| ln Vivo |
In vivo, rosarin has been shown to inhibit the expression of iNOS, IL-1β, and TNF-α in the kidney and prefrontal cortex of the brain in mice. This suggests that it can exert systemic anti-inflammatory effects and cross the blood-brain barrier to modulate neuroinflammation. Its adaptogenic effects on the HPA axis are also observed in vivo.
|
| Enzyme Assay |
Cell-free assays for rosarin measure its ability to inhibit iNOS, IL-1β, and TNF-α. Its anti-inflammatory activity can be assessed in cell-free systems using recombinant proteins. Its molecular weight (428.43) is confirmed by mass spectrometry. Its purity (99.95%) is confirmed by HPLC. Its solubility in DMSO (145 mg/mL) is documented.
|
| Cell Assay |
Cellular assays for rosarin are performed to evaluate its anti-inflammatory effects. In microglial or macrophage cell lines, its ability to suppress the expression of iNOS, IL-1β, and TNF-α is measured. Its neuroprotective effects are studied in neuronal cell cultures exposed to inflammatory stimuli. These assays confirm its mechanism of action.
|
| Animal Protocol |
In vivo animal experiments for rosarin involve mouse models where its effect on the expression of pro-inflammatory factors in the kidney and brain is measured. Its adaptogenic effects are studied in models of stress, where its modulation of the HPA axis is assessed. These studies confirm its in vivo anti-inflammatory and neuroprotective activities.
|
| ADME/Pharmacokinetics |
Rosarin has a molecular weight of 428.43 and a molecular formula of C20H28O10. It is a cinnamyl alcohol glycoside. It is soluble in DMSO (145 mg/mL). For storage, the powder can be kept at -20°C for 3 years. In vivo, it can be formulated with 10% DMSO, 40% PEG300, 5% Tween 80, and 45% saline for administration.
|
| Toxicity/Toxicokinetics |
Rosarin is generally considered safe based on its use in traditional medicine. No significant toxicity has been reported. Its safety profile is consistent with other Rhodiola rosea extracts. However, comprehensive toxicology studies are lacking. It is not an approved drug and is intended for research use.
|
| References | |
| Additional Infomation |
Rosarin is an O-acyl carbohydrate. It has been reported to be found in Rhodiola rosea, Rhodiola saba, and other organisms with relevant data. See also: Roots (parts) of Sedum species.
Rosarin is a cinnamyl alcohol glycoside isolated from Rhodiola rosea. It exhibits anti-inflammatory and neuroprotective effects by suppressing the expression of iNOS, IL-1β, and TNF-α. It supports stress adaptation, cognitive function, and fatigue reduction through modulation of the HPA axis. It is a research compound with potential adaptogenic and neuroprotective applications. |
| Molecular Formula |
C20H28O10
|
|---|---|
| Molecular Weight |
428.4303
|
| Exact Mass |
428.168
|
| CAS # |
84954-93-8
|
| PubChem CID |
10320370
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
730.8±60.0 °C at 760 mmHg
|
| Flash Point |
395.8±32.9 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.635
|
| LogP |
2.03
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
30
|
| Complexity |
540
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C1=CC=C(C=C1)/C=C/CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H](O3)CO)O)O)O)O)O
|
| InChi Key |
IEBFEMIXXHIISM-YZOUKVLTSA-N
|
| InChi Code |
InChI=1S/C20H28O10/c21-9-12-14(22)17(25)20(29-12)28-10-13-15(23)16(24)18(26)19(30-13)27-8-4-7-11-5-2-1-3-6-11/h1-7,12-26H,8-10H2/b7-4+/t12-,13+,14-,15+,16-,17+,18+,19+,20+/m0/s1
|
| Chemical Name |
(2R,3S,4S,5R,6R)-2-[[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-6-[(E)-3-phenylprop-2-enoxy]oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~233.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.84 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3341 mL | 11.6705 mL | 23.3410 mL | |
| 5 mM | 0.4668 mL | 2.3341 mL | 4.6682 mL | |
| 10 mM | 0.2334 mL | 1.1671 mL | 2.3341 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
